4-Aminoquinoline derivatives as novel Mycobacterium tuberculosis GyrB inhibitors: Structural optimization, synthesis and biological evaluation

European Journal of Medicinal Chemistry

Volumn 103, Issue , 2015, Pages 1-16

  Medapi, Brahmam ^a   Suryadevara, Priyanka ^a   Renuka, Janupally ^a   Sridevi, Jonnalagadda Padma ^a   Yogeeswari, Perumal ^a   Sriram, Dharmarajan ^a  

^a BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

Author keywords

Cytotoxicity; Differential scanning fluorimetry; DNA gyrase B; DNA supercoil assay; Mycobacterium tuberculosis

Indexed keywords

4 AMINOQUINOLINE DERIVATIVE; 4 [[4 (3 MORPHOLINOPROPOXY)PHENYL]AMINO] 5 (TRIFLUOROMETHYL)QUINOLINE 3 CARBOHYDRAZIDE; 4 [[4 (3 MORPHOLINOPROPOXY)PHENYL]AMINO]QUINOLINE 3 CARBOHYDRAZIDE; 4 [[4 [(3 MORPHOLINOPROPYL)AMINO]PHENYL]AMINO] 6 (TRIFLUOROMETHYL)QUINOLINE 3 CARBOHYDRAZIDE; 4 [[4 [(3 MORPHOLINOPROPYL)AMINO]PHENYL]AMINO]QUINOLINE 3 CARBOHYDRAZIDE; 4 [[4 [3 (4 ETHYLPIPERAZIN 1 YL)PROPOXY]PHENYL]AMINO] 6 (TRIFLUOROMETHYL)QUINOLINE 3 CARBOHYDRAZIDE; 4 [[4 [[3 (4 ETHYLPIPERAZIN 1 YL)PROPYL]AMINO]PHENYL]AMINO]QUINOLINE 3 CARBOHYDRAZIDE; 6 FLUORO 4 [[4 [(3 MORPHOLINOPROPYL)AMINO]PHENYL]AMINO]QUINOLINE 3 CARBOHYDRAZIDE; 6 FUORO 4 [[4 (3 MORPHOLINOPROPOXY)PHENYL]AMINO]QUINOLINE 3 CARBOHYDRAZIDE; 6 METHOXY 4 [[4 (3 MORPHOLINOPROPOXY)PHENYL]AMINO]QUINOLINE 3 CARBOHYDRAZIDE; 6 METHOXY 4 [[4 [(3 MORPHOLINOPROPYL)AMINO]PHENYL]AMINO]QUINOLINE 3 CARBOHYDRAZIDE; DNA TOPOISOMERASE (ATP HYDROLYSING) B; ETHYL 4 [[4 (3 MORPHOLINOPROPOXY)PHENYL]AMINO] 6 (TRIFLUOROMETHYL)QUINOLINE 3 CARBOXYLATE; ETHYL 4 [[4 (3 MORPHOLINOPROPOXY)PHENYL]AMINO]QUINOLINE 3 CARBOXYLATE; ETHYL 4 [[4 [(3 MORPHOLINOPROPOXY)AMINO]PHENYL]AMINO]QUINOLINE 3 CARBOXYLATE; ETHYL 4 [[4 [(3 MORPHOLINOPROPYL)AMINO]PHENYL]AMINO] 6 (TRIFLUOROMETHYL)QUINOLINE 3 CARBOXYLATE; ETHYL 4 [[4 [3 (4 ETHYLPIPERIZIN 1 YL)PROPOXY]PHENYL]AMINO] 6 (TRIFLUOROMETHYL)QUINOLINE 3 CARBOXYLATE; ETHYL 4 [[4 [3 (4 ETHYLPIPERIZIN 1 YL)PROPOXY]PHENYL]AMINO] 6 FLUOROQUINOLINE 3 CARBOXYLATE; ETHYL 4 [[4 [3 (4 ETHYLPIPERIZIN 1 YL)PROPOXY]PHENYL]AMINO] 6 METHOXYQUINOLINE 3 CARBOXYLATE; ETHYL 4 [[4 [3 (4 ETHYLPIPERIZIN 1 YL)PROPOXY]PHENYL]AMINO]QUINOLINE 3 CARBOXYLATE; ETHYL 4 [[4 [[3 (4 ETHYLPIPERIZIN 1 YL)PROPYL]AMINO]PHENYL]AMINO] 6 (TRIFLUOROMETHYL)QUINOLINE 3 CARBOXYLATE; ETHYL 4 [[4 [[3 (4 ETHYLPIPERIZIN 1 YL)PROPYL]AMINO]PHENYL]AMINO] 6 FLUOROQUINOLINE 3 CARBOXYLATE; ETHYL 4 [[4 [[3 (4 ETHYLPIPERIZIN 1 YL)PROPYL]AMINO]PHENYL]AMINO] 6 METHOXYQUINOLINE 3 CARBOXYLATE; ETHYL 4 [[4 [[3 (4 ETHYLPIPERIZIN 1 YL)PROPYL]AMINO]PHENYL]AMINO]QUINOLINE 3 CARBOXYLATE; ETHYL 6 FLUORO 4 [[4 (3 MORPHOLINOPROPOXY)PHENYL]AMINO]QUINOLINE 3 CARBOXYLATE; ETHYL 6 FLUORO 4 [[4 (3 MORPHOLINOPROPYL)AMINO]PHENYL]AMINO]QUINOLINE 3 CARBOXYLATE; ETHYL 6 METHOXY 4 [[4 (3 MORPHOLINOPROPOXY)PHENYL]AMINO]QUINOLINE 3 CARBOXYLATE; ETHYL 6 METHOXY 4 [[4 (3 MORPHOLINOPROPYL)AMINO]PHENYL]AMINO]QUINOLINE 3 CARBOXYLATE; ISOMERASE INHIBITOR; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; 4-AMINOQUINOLINE; AMINOQUINOLINE DERIVATIVE; DNA TOPOISOMERASE (ATP HYDROLYSING); GYRASE INHIBITOR;

ANIMAL CELL; ANTIBACTERIAL ACTIVITY; ARTICLE; BINDING AFFINITY; BIOLOGICAL ACTIVITY; CONTROLLED STUDY; DIFFERENTIAL SCANNING FLUORIMETRY; DNA SUPERCOILING; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; FLUOROMETRY; IC50; IN VITRO STUDY; MACROPHAGE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; TEMPERATURE; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; MICROBIAL SENSITIVITY TEST; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

AMINOQUINOLINES; ANTITUBERCULAR AGENTS; DNA GYRASE; DOSE-RESPONSE RELATIONSHIP, DRUG; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; MYCOBACTERIUM TUBERCULOSIS; STRUCTURE-ACTIVITY RELATIONSHIP; TOPOISOMERASE II INHIBITORS;

EID: 84940030864     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2015.06.032     Document Type: Article

References (22)

1. World Health Organization, Global Tuberculosis Control, WHO, 2014 report: http://www.who.int/iris/bitstream/10665/137094/1/9789241564809-eng.pdf?ua=1.
2. K.J. Seung, D.B. Omatayo, S. Keshavjee, J.J. Furin, P.E. Farmer, H. Satti, Early outcomes of MDR-TB treatment in a high HIV-prevalence setting in Southern Africa, Plos. One 4 (9) (2009) e7186.
3. G. Sotqiu, G. Ferrara, A. Matteelli, M.D. Richardson, R. Centis, S. Ruesch-Gerdes, O. Toungoussova, J.P. Zellweger, A. Spanevello, D. Cirillo, C. Lange, G.B. Migliori, Epidemiology and clinical management of XDR-TB: a systematic review by TBNET, Eur. Respir. J. 33 (2009) 871-881.
4. Z.F. Udwadia, R.A. Amale, K.K. Ajbani, C. Rodrigues, Totally drug-resistant tuberculosis in India, Clin. Infect. Dis. 54 (2012) 579-581.
5. J.H.M. Cabral, A.P. Jackson, C.V. Smith, N. Shikotra, A. Maxwell, R.C. Liddington, Crystal structure of the breakage-reunion domain of DNA gyrase, Nature 388 (1997) 903-906.
6. S. Chopra, K. Matsuyama, T. Tran, J.P. Malerich, B. Wan, S.G. Franzblau, S. Lun, H. Guo, M.C. Maiga, W.R. Bishai, P.B. Madrid, Evaluation of gyrase B as a drug target in Mycobacterium tuberculosis, J. Antimicrob. Chemother. 67 (2012) 415-421.
7. R.J. Lewis, O.M. Singh, C.V. Smith, T. Skarzynski, A. Maxwell, A.J. Wonacott, D.B. Wigley, The nature of inhibition of DNA gyrase by the coumarins and the cyclothialidines revealed by X-ray crystallography, EMBO. J. 15 (1996) 1412-1420.
8. P.S. Charifson, A.L. Grillot, T.H. Grossman, J.D. Parsons, M. Badia, S. Bellon, D.D. Deininger, J.E. Drumm, C.H. Gross, A. LeTiran, Y. Liao, N. Mani, D.P. Nicolau, E. Perola, S. Ronkin, D. Shannon, L.L. Swenson, Q. Tang, P.R. Tessier, S.K. Tian, M. Trudeau, T. Wang, Y. Wei, H. Zhang, D. Stamos, Novel dual-targeting benzimidazole urea inhibitors of DNA gyrase and topoisomerase IV possessing potent antibacterial activity: intelligent design and evolution through the judicious use of structure-guided design and structure-activity relationships, J. Med. Chem. 51 (2008) 5243-5263.
9. P.S. Shirude, P. Madhavapeddi, J.A. Tucker, K. Murugan, V. Patil, H. Basavarajappa, A.V. Raichurkar, V. Humnabadkar, S. Hussein, S. Sharma, V.K. Ramya, C.B. Narayan, T.S. Balganesh, V.K. Sambandamurthy, Aminopyrazinamides: novel and specific GyrB inhibitors that kill replicating and nonreplicating Mycobacterium tuberculosis, ACS Chem. Biol. 8 (2013) 519-523.
10. M.G. Kale, A. Raichurkar, H.P.S.D. Waterson, D. McKinney, M.R. Manjunatha, U. Kranthi, K. Koushik, L.K. Jena, V. Shinde, S. Rudrapatna, S. Barde, V. Humnabadkar, P. Madhavapeddi, H. Basavarajappa, A. Ghosh, V. Ramya, S. Guptha, S. Sharma, P. Vachaspati, K. Kumar, J. Giridhar, J. Reddy, V. Panduga, S. Ganguly, V. Ahuja, S. Gaonkar, C.N. Kumar, D. Ogg, J.A. Tucker, P.A. Boriack-Sjodin, S.M. de Sousa, V.K. Sambandamurthy, S.R. Ghorpade, Thiazolopyridine ureas as novel antitubercular agents acting through inhibition of DNA Gyrase B, J. Med. Chem. 56 (2013) 8834-8848.
11. Glide, Version 5.8, Schrödinger, LLC, New York, NY, 2012.
12. V.U. Jeankumar, J. Renuka, P. Santosh, V. Soni, J.P. Sridevi, P. Suryadevara, P. Yogeeswari, D. Sriram, Thiazole-aminopiperidine hybrid analogues: design and synthesis of novel Mycobacterium tuberculosis GyrB inhibitors, Eur. J. Med. Chem. 70 (2013) 143-153.
13. I.P. Höglund, S. Silver, M.T. Engström, H. Salo, A. Tauber, H.K. Kyyrönen, P. Saarenketo, A.M. Hoffrén, K. Kokko, K. Pohjanoksa, J. Sallinen, J.M. Savola, S. Wurster, O.A. Kallatsa, Structure-activity relationship of quinoline derivatives as potent and selective alpha(2C)-adrenoceptor antagonists, J. Med. Chem. 49 (2006) 6351-6363.
14. S. Eswaran, A.V. Adhikari, N.K. Pal, I.H. Chowdhury, Design and synthesis of some new quinoline-3-carbohydrazone derivatives as potential anti-mycobacterial agents, Bioorg. Med. Chem. Lett. 20 (2010) 1040-1044.
15. K.D. Thomas, A.V. Adhikari, S. Telkar, I.H. Chowdhury, R. Mahmood, N.K. Pal, G. Row, E. Sumesh, Design, synthesis and docking studies of new quinoline-3-carbohydrazide derivatives as antitubercular agents, Eur. J. Med. Chem. 46 (2011) 5283-5292.
16. J.A. Ali, A.P. Jackson, A.J. Howells, A. Maxwell, The 43-kilodalton N-terminal fragment of the DNA gyrase B protein hydrolyzes ATP and binds coumarin drugs, Biochemistry 32 (1993) 2717-2724.
17. J. Renuka, K.I. Reddy, K. Srihari, V.U. Jeankumar, M. Shravan, J.P. Sridevi, P. Yogeeswari, K.S. Babu, D. Sriram, Design, synthesis, biological evaluation of substituted benzofurans as DNA gyraseB inhibitors of Mycobacterium tuberculosis, Bioorg. Med. Chem. 22 (2014) 4924-4934.
18. A.J. Ryan, N.M. Gray, P.N. Lowe, C.W. Chung, Effect of detergent on "promiscuous" inhibitors, J. Med. Chem. 46 (2003) 3448-3451.
19. S.G. Franzblau, R.S. Witzig, J.C. McLaughlin, P. Torres, G. Madico, A. Hernandez, M.T. Degnan, M.B. Cook, V.K. Quenzer, R.M. Ferguson, R.H. Gilman, Rapid, low-technology MIC determination with clinical Mycobacterium tuberculosis isolates by using the microplate Alamar Blue assay, J. Clin. Microbiol. 36 (1998) 362-366.
20. M. Ferrari, M.C. Fornasiero, A.M. Isetta, MTT colorimetric assay for testing macrophage cytotoxic activity in vitro, J. Immunol. Methods 131 (1990) 165-172.
21. V.U. Jeankumar, J. Renuka, V.K. Pulla, V. Soni, J.P. Sridevi, P. Suryadevara, M. Shravan, R. Medishetti, P. Kulkarni, P. Yogeeswari, D. Sriram, Development of novel N-linked aminopiperidine-based mycobacterial DNA gyrase B inhibitors: scaffold hopping from known antibacterial leads, Int. J. Antimicrob. Agents 43 (2014) 269-278.
22. F.H. Niesen, H. Berglund, M. Vedadi, The use of differential scanning fluorimetry to detect ligand interactions that promotes protein stability, Nat. Protoc. 2 (2007) 2212-2221.